Risk adjusted net present value: What is the current valuation of Novo Nordisk’s (Insulin icodec + Semaglutide)?

VIENNA — Rheumatologists are still struggling with what to do when multiple state-of-the-art treatments have failed to bring rheumatoid arthritis (RA) under control, reports here

In a Q2 financial report, BioNTech announced that it would quit the joint development of acasunlimab with Genmab as it focuses on its antibody drug